Postcholecystectomy Syndrome Clinical Trial
Official title:
Effect of Rowachol on Prevention of Postcholecystectomy Syndrome After Laparoscopic Cholecystectomy
Postcholecystectomy syndrome (PCS) includes a heterogeneous group of diseases, usually
manifested by the presence of abdominal symptoms following gallbladder removal. The
pathogenesis of PCS has not been identified; therefore there is no consensus of medical
treatment on PCS. The Action of Rowachol are to inhibit hepatic 3-hydroxy-3-methylglutaric
acid(HMG)-coenzyme A(CoA) reductase, to inhibits cholesterol nucleation in bile from
patients with cholesterol gallstones, and to promote biliary lipid secretion.
The purpose of this study is to determine whether Rowachol is useful in the prevention of
PCS and symptoms change after laparoscopic cholecystectomy
n/a
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06405906 -
A Randomized Controlled Trial Comparing Fat-free Versus Balanced (WHO) Diet in Gallstone Disease
|
N/A | |
| Recruiting |
NCT03401424 -
Comparison of Two Kinds of Biliary Intestinal Reconstruction in Cholangiectasia
|
N/A |